Mineralys Therapeutics Inc. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
lorundrostatThis study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension	Hypertension	Phase 3	À vérifier	United States, Australia, Bulgaria, Canada, France, Germany, Italy, Netherlands, …	À vérifier
lorundrostatThis study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension	Hypertension	Phase 3	À vérifier	United States, Australia, Bulgaria, Canada, France, Germany, Italy, Netherlands, Poland, Puerto Rico, Romania, Spain, United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
lorundrostat	Hypertension	Phase 3	NCT05968430	Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.